<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380951</url>
  </required_header>
  <id_info>
    <org_study_id>szwy20110610</org_study_id>
    <nct_id>NCT01380951</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B (CHB)</brief_title>
  <official_title>Clinical Study of Telbivudine on Liver Cirrhosis in Patients With Chronic Hepatitis B</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Fifth People's Hospital of Suzhou</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Fifth People's Hospital of Suzhou</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiviral treatment on Chronic Hepatitis B (CHB) patients with liver cirrhosis is compulsory
      and effective. Telbivudine, which is superior to lamivudine in the treatment of CHB,is
      considered to be appropriate for the antiviral treatment on CHB patients with liver
      cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Antiviral therapy on CHB patients with liver cirrhosis is compulsory and effective. Diseases
      development can be prevented or delayed if the virus is depressed successfully. Lamivudine is
      often used and usually has good efficacy. However, lamivudine resistance and virus mutation
      happens a lot. Telbivudine, which is superior to lamivudine in the treatment of CHB,is
      considered to be appropriate for the antiviral treatment on CHB patients with liver
      cirrhosis.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2011</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum HBV DNA</measure>
    <time_frame>48 weeks</time_frame>
    <description>serum HBV DNA negativity and decline from baseline at week 48</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum HBeAg</measure>
    <time_frame>48 weeks</time_frame>
    <description>rate of HBeAg seroconversion and HBeAg loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child-pugh score</measure>
    <time_frame>48 weeks</time_frame>
    <description>the average decline of Child-pugh score at week 48 from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Liver Cirrhosis</condition>
  <condition>Chronic Hepatitis B</condition>
  <arm_group>
    <arm_group_label>telbivudine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>telbivudine</intervention_name>
    <description>telbivudine 600mg/d 96 weeks</description>
    <arm_group_label>telbivudine</arm_group_label>
    <other_name>Sebivo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  liver cirrhosis with CHB

          -  without history of antiviral therapy or discontinued antiviral therapy for more than 6
             months

          -  for patients with compensated liver cirrhosis: HBV DNA≥4log copies/ml if HBeAg
             positive,HBV DNA≥3log copies/ml if HBeAg negative

          -  for patients with uncompensated liver cirrhosis:HBV DNA positive

        Exclusion Criteria:

          -  coinfection with HCV,HDV and HIV

          -  AFP≥100mg/L or HCC diagnosed by iconography

          -  with severe cardiovascular, respiratory and endocrinology diseases or autoimmune
             diseases
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chuanwu Zhu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Fifth People's Hospital of Suzhou</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>the Fifth People's Hospital of Suzhou</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Honghao Zhang, B.A.</last_name>
      <email>zhanghonghao@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Chuanwu Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 27, 2011</last_update_posted>
  <responsible_party>
    <name_title>Chuanwu Zhu</name_title>
    <organization>the Fifth People's Hospital of Suzhou</organization>
  </responsible_party>
  <keyword>liver cirrhosis</keyword>
  <keyword>chronic hepatitis B</keyword>
  <keyword>antiviral therapy</keyword>
  <keyword>telbivudine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telbivudine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

